Obesity and Alzheimer's drugs pack one-two punch to power Eli Lilly higher in 2024

Investor optimism for Eli Lilly‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story.

Source link

About The Author

Scroll to Top